Trial Profile
A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Intramuscular (IM) Injection of REGN2222 Produced by 2 Different Cell Lines in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Suptavumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 21 Jul 2016 New trial record